Navigation Links
Targanta Submits Oritavancin New Drug Application
Date:2/11/2008

ommercializing innovative antibiotics to treat serious infections in the hospital and other institutional settings. The Company's pipeline includes oritavancin, a semi-synthetic lipoglycopeptide antibiotic currently awaiting U.S. regulatory approval, as well as a number of antibacterial agents in pre-clinical development. The Company has operations in Cambridge, MA, Indianapolis, IN, and Montreal, Quebec, Canada. To find out more about Targanta Therapeutics Corp. (Nasdaq: TARG), visit our website at http://www.targanta.com.

Safe Harbor Statement

This press release contains "forward-looking statements" that are made pursuant to the safe harbor provisions Section 21E of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risk and uncertainties, and actual future results may differ materially. Forward-looking statements may be significantly impacted by certain risks and uncertainties described in Targanta's filings with the Securities and Exchange Commission. The risks and uncertainties referred to above include, but are not limited to, risks related to Targanta's dependence on the success of oritavancin; delays in obtaining or a failure to obtain regulatory approval for Targanta's product candidates; failure of any approved product to achieve significant commercial acceptance in the medical community or receive reimbursement by third-party payors; unfavorable clinical trial results; failure to maintain and protect Targanta's intellectual property assets and to avoid infringing the intellectual property rights of others; competition from other pharmaceutical or biotechnology companies; Targanta's potential inability to init
'/>"/>

SOURCE Targanta Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Targanta to Present at Lazard Capital Markets Fourth Annual Healthcare Conference
2. Targanta to Present at 9th Annual Mass Opportunities Investment Conference
3. Targanta Therapeutics Announces Pricing of its Initial Public Offering
4. Targanta Therapeutics to Have Significant Presence at 47th Annual ICAAC Meeting
5. MedImmune Submits Biologics License Application to FDA for Motavizumab
6. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
7. Exelixis Submits XL139 Diligence Report to Bristol-Myers Squibb
8. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
9. Cephalon Submits Supplemental New Drug Application for FENTORA
10. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
11. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 2014 2014 Deep Research Report ... a professional and in-depth research report on the ... information, like its definition, classification, application, and industry ... report covers the international market analysis, including China’s ... the US, Europe, Asia, China, Japan etc. regions) ...
(Date:11/21/2014)... VANCOUVER , Nov. 20, 2014 /CNW/ - ... pleased to announce that it has closed a ... special warrants for approximately C$3.7 million.  Cormark Securities ... agents in the Brokered Offering for a syndicate ... and PI Financial Corp. (collectively the "Agents"). Concurrently ...
(Date:11/18/2014)... Nov. 18, 2014 Cord Blood Registry® (CBR®) ... the 10th Annual World Stem Cell Summit, the largest global ... 2014 World Stem Cell Summit will be held December 3-5 ... . The World Stem Cell ... lifesaving cures and therapies, convening the most prominent figures in ...
(Date:11/18/2014)... pH measurement and control is vital in a ... food and beverage industries. But what exactly is pH, ... sensors work? METTLER TOLEDO has produced a guide to ... these questions and more. , METTLER TOLEDO provides a ... The actual sensor, the pH electrode, is therefore the ...
Breaking Biology Technology:Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Aequus Pharmaceuticals closes $4.2 million private placement financing 2Aequus Pharmaceuticals closes $4.2 million private placement financing 3Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3pH Guide from METTLER TOLEDO Explains Measurement, Theory and Practice of pH Applications 2
... HAVEN, Conn. , Jan. 19 ... Richard J. Carroll to the newly created position of ... over 20 years of sales, marketing, research, and general management ... joining HistoRx in 2009, he was Vice President of Clinical ...
... , ABBOTT PARK, Ill., Jan. 18 Working directly ... Abbott (NYSE: ABT ) is expanding its ... provide $2.5 million in grant funding and donations of ... An initial quantity of Abbott pharmaceutical and nutritional products ...
... , , RANCHO SANTA MARGARITA, Calif. , ... is critically important for the development, growth, and maintenance of a ... of vitamin D within minutes of whole body exposure to sunlight. ... system evolved by chance," states Dr. John Cannell , Executive ...
Cached Biology Technology:HistoRx Names Dick Carroll, Ph.D. as VP of Clinical Research 2HistoRx Names Dick Carroll, Ph.D. as VP of Clinical Research 3Updated Abbott Statement: To Help Respond to Growing Health Crisis, Abbott Increases Aid to $2.5 Million for Haiti Relief and Recovery Efforts 2Updated Abbott Statement: To Help Respond to Growing Health Crisis, Abbott Increases Aid to $2.5 Million for Haiti Relief and Recovery Efforts 3Updated Abbott Statement: To Help Respond to Growing Health Crisis, Abbott Increases Aid to $2.5 Million for Haiti Relief and Recovery Efforts 4Cancer, Heart Disease, Stroke, Diabetes, Chronic Pain and Depression Share a Major Pathology Factor 2Cancer, Heart Disease, Stroke, Diabetes, Chronic Pain and Depression Share a Major Pathology Factor 3
(Date:11/12/2014)... PALM BEACH GARDENS, Fla. , Nov. 12, 2014 ... management solutions, announced today that its U.are.U ® ... upscale retail bakery chain in Central Mexico ... solution in June 2014 to eliminate payroll issues caused ... Prior to installing the U.are.U fingerprint readers, Montparnasse ...
(Date:11/7/2014)... -- Leading Biometric companies aim to provide consumers ... transactions.  Companies in focus today are: NXT-ID, Inc. (NASDAQ: ... ), Google Inc. (NASDAQ: GOOG ), Microsoft Corporation ... EBAY ) and MasterCard Inc. (NYSE: MA) NXT-ID, ... authentication company focused on the growing mobile commerce is pleased ...
(Date:11/5/2014)... biology in the UTSA College of Sciences, is ... to receive a two-year $300,00 National Science Foundation ... The funding supports President Obama,s BRAIN Initiative, a ... technology that will demystify complex brain processes. ... are broken into the interactions of multiple components, ...
Breaking Biology News(10 mins):Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3
... Water-associated infectious disease outbreaks are more likely ... density is growing, according to a new global ... the risk for these outbreaks. Ohio State ... about 1,428 water-associated disease outbreaks that were reported ...
... Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... financial results for its fourth quarter and year ended December ... of 2011 was $5.9 million, a decrease of 14% compared ... income for the fourth quarter of 2011 was $959,000, or ...
... from the University of Notre Dame, the University of Iowa ... million from the National Science Foundation to answer a fundamental ... extent, do other species that depend on it evolve as ... a fruit fly specifically the apple maggot fly ...
Cached Biology News:High population density is greatest risk factor for water-linked diseases 2High population density is greatest risk factor for water-linked diseases 3High population density is greatest risk factor for water-linked diseases 4Aware, Inc. Reports Fourth Quarter and 2011 Financial Results 2Aware, Inc. Reports Fourth Quarter and 2011 Financial Results 3Aware, Inc. Reports Fourth Quarter and 2011 Financial Results 4Aware, Inc. Reports Fourth Quarter and 2011 Financial Results 5Notre Dame biologists tackling big question in evolution 2
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
... chemiluminescence efficiencies and the chemistry of light ... added benefit that they require simple triggering ... signal. This benefit has been exploited to ... These compounds can also be easily modified ...
... The Deletion Kit for Kilo-Sequencing is ... DNA fragments cloned into the multiple cloning ... or pUC-related plasmid or phagemid vectors (pUC18/19). ... unidirectional deletions in the target DNA, thereby ...
... network client/server version of Freezerworks Unlimited includes 2 ... labs and facilitates the sharing of freezers by ... information. Network ... 601); 13 in monitor with 256 colors; OS ...
Biology Products: